Prague Med. Rep. 2023, 124, 230-241
https://doi.org/10.14712/23362936.2023.18
Effect of Convalescent Plasma Therapy on Mortality and Viral Load in Severely Ill Patients with COVID-19
References
1. Balík, M., Bohoněk, M., Černý, V., Holub, M., Kümpel, P., Plíšek, S., Roháčová, H. (2020) Doporučený postup pro použití rekonvalescentní plazmy v léčbě dospělých pacientů s COVID-19. Česká Společnost Anesteziologie, Resuscitace a Intenzivní Medicíny ČLS JEP. Available at: https://www.csarim.cz/getmedia/975c0db9-cc03-4b15-812a-377d41713e61/08_dp_covid_stl_csarim_sil_rekonvalesc_plazma_300420_2.pdf.aspx (Accessed 12. 12. 2022)
2. 2021) Convalescent plasma for hospitalized patients with COVID-19: An open-label, randomized controlled trial. Nat. Med. 27, 2012–2024.
< , P., Callum, J., Jamula, E., Cook, R., Heddle, N. M., Tinmouth, A., Zeller, M. P., Beaudoin-Bussières, G., Amorim, L., Bazin, R., Loftsgard, K. C., Carl, R., Chassé, M., Cushing, M. M., Daneman, N., Devine, D. V., Dumaresq, J., Fergusson, D. A., Gabe, C., Glesby, M. J., Li, N., Liu, Y., McGeer, A., Robitaille, N., Sachais, B. S., Scales, D. C., Schwartz, L., Shehata, N., Turgeon, A. F., Wood, H., Zarychanski, R., Finzi, A.; CONCOR-1 Study Group; Arnold, D. M. (https://doi.org/10.1038/s41591-021-01488-2>
3. 1890) Untersuchungen über das Zustandekommen der Diphtherie-Immunität bei Thieren. Dtsch. Med. Wochenschr. 1890, 1145–1148.
, E. A. (
4. Bohoněk, M., Černý, V., Holub, M., Dlouhý, P., Vašáková, M. (2021) Mezioborové stanovisko (evidenční číslo ČSARIM: 18/2021) k podávání rekonvalescentní plazmy u pacientů s COVID-19. Česká Společnost Anesteziologie, Resuscitace a Intenzivní Medicíny ČLS JEP. Available at: https://www.csarim.cz/getmedia/0d4a80ec-41de-459b-aa2c-1f6a2f1042a5/2021_PP_18_CSARIM_STL_SIL_CPFS_Rekonv_plazma_final_020321.pdf
5. 2011) Emil von Behring (1854–1917): Medicine’s first Nobel laureate. Singapore Med. J. 52, 1–2.
, A., Tan, S. Y. (
6. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. NIH COVID-19 Treatment Guidelines. Available at: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf
7. 2022) The relationship between COVID-19 viral load and disease severity: A systematic review. Immun. Inflamm. Dis. 10, e580.
< , O., Afsahi, A. M., Pashaei, Z., Mojdeganlou, H., Karimi, A., Habibi, P., Barzegary, A., Fakhfouri, A., Mirzapour, P., Janfaza, N., Dehghani, S., Afroughi, F., Dashti, M., Khodaei, S., Mehraeen, E., Voltarelli, F., Sabatier, J.-M., SeyedAlinaghi, S. (https://doi.org/10.1002/iid3.580>
8. 2023) Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: A randomized clinical trial. Nat. Cancer 4, 96–107.
, C. M., Janssen, M., Schäkel, U., Gall, J., Leo, A., Stelmach, P., Weber, S. F., Krisam, J., Baumann, L., Stermann, J., Merle, U., Weigand, M. A., Nusshag, C., Bullinger, L., Schrezenmeier, J.-F., Bornhäuser, M., Alakel, N., Witzke, O., Wolf, T., Vehreschild, M. J. G. T., Schmiedel, S., Addo, M. M., Herth, F., Kreuter, M., Tepasse, P.-R., Hertenstein, B., Hänel, M., Morgner, A., Kiehl, M., Hopfer, O., Wattad, M.-A., Schimanski, C. C., Celik, C., Pohle, T., Ruhe, M., Kern, W. V., Schmitt, A., Lorenz, H.-M., Souto-Carneiro, M., Gaeddert, M., Halama, N., Meuer, S., Kräusslich, H.-G., Müller, B., Schnitzler, P., Parthé, S., Bartenschlager, R., Gronkowski, M., Klemmer, J., Schmitt, M., Dreger, P., Kriegsmann, K., Schlenk, R. F., Müller-Tidow, C. (
9. 2020) SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat. Commun. 11, 5493.
< , J., Regan, J., Coxen, K., Corry, H., Wong, C., Rosenthal, A., Worrall, D., Giguel, F., Piechocka-Trocha, A., Atyeo, C., Fischinger, S., Chan, A., Flaherty, K. T., Hall, K., Dougan, M., Ryan, E. T., Gillespie, E., Chishti, R., Li, Y., Jilg, N., Hanidziar, D., Baron, R. M., Baden, L., Tsibris, A. M., Armstrong, K. A., Kuritzkes, D. R., Alter, G., Walker, B. D., Yu, X., Li, J. Z. (https://doi.org/10.1038/s41467-020-19057-5>
10. 2006) Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann. Intern. Med. 145, 599–609.
< , T. C., Kilbane, E. M., Jackson, J. L., Hoffman, S. L. (https://doi.org/10.7326/0003-4819-145-8-200610170-00139>
11. 2022) Antibody response against SARS-CoV-2 infection: Implications for diagnosis, treatment and vaccine development. Int. Rev. Immunol. 41, 393–413.
< , A., Ascione, A., Flego, M. (https://doi.org/10.1080/08830185.2021.1929205>
12. 2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 397, 1637–1645.
Collaborative Group (
13. 2021) Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N. Engl. J. Med. 384, 1503–1516.
< , I. O., Bräu, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D., Aziz, M. S., Cooper, N., Douglas, I. S., Savic, S., Youngstein, T., Del Sorbo, L., Cubillo Gracian, A., De La Zerda, D. J., Ustianowski, A., Bao, M., Dimonaco, S., Graham, E., Matharu, B., Spotswood, H., Tsai, L., Malhotra, A. (https://doi.org/10.1056/NEJMoa2028700>
14. Turek, P. (2020) Darování plazmy po prodělané infekci koronavirem (COVID-19). Transfuzní Oddělení, Fakultní Thomayerova nemocnice. Available at: https://www.ftn.cz/upload/ftn/Kliniky/Transfuzni_odd/Dokumenty/TN_TRA_COVID-19_nabor.pdf
15. 2020) Vyšetření anti-SARS-CoV-2 virus-neutralizačním testem a IgG Elisa testem Euroimmun. Transfuze a Hematologie Dnes 26, 27.
, P., Dresler, J., Hamšíková, E., Gašová, Z., Dušková, D., Ibrahimová, M., Kabíčková, H., Kubíčková, P. (
16. 2021) Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. Am. J. Emerg. Med. 40, 11–14.
< Moradi, E., Teimouri, A., Rezaee, R., Morovatdar, N., Foroughian, M., Layegh, P., Rezvani Kakhki, B., Ahmadi Koupaei, S. R., Ghorani, V. (https://doi.org/10.1016/j.ajem.2020.12.003>
17. 2020) Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin. Infect. Dis. 71, 2688–2694.
< , X., Guo, X., Xin, Q., Pan, Y., Hu, Y., Li, J., Chu, Y., Feng, Y., Wang, Q. (https://doi.org/10.1093/cid/ciaa721>
18. Writing Committee for the REMAP-CAP Investigators; 2021) Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: A randomized clinical trial. JAMA 326, 1690–1702.
, L. J., Turgeon, A. F., McQuilten, Z. K., McVerry, B. J., Al-Beidh, F., Annane, D., Arabi, Y. M., Arnold, D. M., Beane, A., Bégin, P., van Bentum-Puijk, W., Berry, L. R., Bhimani, Z., Birchall, J. E., Bonten, M. J. M., Bradbury, C. A., Brunkhorst, F. M., Buxton, M., Callum, J. L., Chassé, M., Cheng, A. C., Cove, M. E., Daly, J., Derde, L., Detry, M. A., De Jong, M., Evans, A., Fergusson, D. A., Fish, M., Fitzgerald, M., Foley, C., Goossens, H., Gordon, A. C., Gosbell, I. B., Green, C., Haniffa, R., Harvala, H., Higgins, A. M., Hills, T. E., Hoad, V. C., Horvat, C., Huang, D. T., Hudson, C. L., Ichihara, N., Laing, E., Lamikanra, A. A., Lamontagne, F., Lawler, P. R., Linstrum, K., Litton, E., Lorenzi, E., MacLennan, S., Marshall, J., McAuley, D. F., McDyer, J. F., McGlothlin, A., McGuinness, S., Miflin, G., Montgomery, S., Mouncey, P. R., Murthy, S., Nichol, A., Parke, R., Parker, J. C., Priddee, N., Purcell, D. F. J., Reyes, L. F., Richardson, P., Robitaille, N., Rowan, K. M., Rynne, J., Saito, H., Santos, M., Saunders, C. T., Serpa Neto, A., Seymour, C. W., Silversides, J. A., Tinmouth, A. A., Triulzi, D. J., Turner, A. M., van de Veerdonk, F., Walsh, T. S., Wood, E. M., Berry, S., Lewis, R. J., Menon, D. K., McArthur, C., Zarychanski, R., Angus, D. C., Webb, S. A., Roberts, D. J., Shankar-Hari, M. (
19. 2021) The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target. Ther. 6, 1–20.
, L., Xie, X., Tu, Z., Fu, J., Xu, D., Zhou, Y. (